Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
Author:
Funder
Scientific and Technological Research Projects in Henan Province
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00277-021-04535-7.pdf
Reference30 articles.
1. Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50(1):74–87. https://doi.org/10.1016/j.pathol.2017.09.006
2. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378(15):1396–1407. https://doi.org/10.1056/NEJMoa1801445
3. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreundschuh M, Ladetto M, Committee EG (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116–v125. https://doi.org/10.1093/annonc/mdv304
4. Tang H, Zhou H, Wei J, Liu H, Qian W, Chen X (2019) Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematology 24(1):446–454. https://doi.org/10.1080/16078454.2019.1614289
5. Abdulla M, Hollander P, Pandzic T, Mansouri L, Ednersson SB, Andersson PO, Hultdin M, Fors M, Erlanson M, Degerman S, Petersen HM, Asmar F, Gronbaek K, Enblad G, Cavelier L, Rosenquist R, Amini RM (2020) Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol 95(1):57–67. https://doi.org/10.1002/ajh.25666
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice;Blood Neoplasia;2024-09
2. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas;Cancer Cell;2024-05
3. Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma;Blood Research;2023-11-15
4. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma;Experimental Hematology & Oncology;2023-08-14
5. Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma;European Journal of Pharmacology;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3